T
Thomas Eigentler
Researcher at University of Tübingen
Publications - 295
Citations - 14387
Thomas Eigentler is an academic researcher from University of Tübingen. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 51, co-authored 259 publications receiving 11484 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas,Igor Puzanov,Reinhard Dummer,Dirk Schadendorf,Omid Hamid,Caroline Robert,F. Stephen Hodi,Jacob Schachter,Anna C. Pavlick,Karl D. Lewis,Lee D. Cranmer,Christian U. Blank,Steven J. O'Day,Paolo A. Ascierto,April K.S. Salama,Kim Margolin,Carmen Loquai,Thomas Eigentler,Tara C. Gangadhar,Matteo S. Carlino,Sanjiv S. Agarwala,Stergios J. Moschos,Jeffrey A. Sosman,Simone M. Goldinger,Ronnie Shapira-Frommer,Rene Gonzalez,John M. Kirkwood,Jedd D. Wolchok,Alexander M.M. Eggermont,Xiaoyun Nicole Li,Wei Zhou,Adriane M Zernhelt,Joy Lis,Scot Ebbinghaus,S. Peter Kang,Adil Daud +35 more
TL;DR: In this article, the efficacy and safety of two pembrolizumab doses versus investigator-choice chemotherapy in patients with ipilimumab-refractory melanoma were compared.
Journal ArticleDOI
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
Lars Hofmann,Andrea Forschner,Carmen Loquai,Simone M. Goldinger,Lisa Zimmer,Selma Ugurel,Maria I. Schmidgen,Ralf Gutzmer,Jochen Utikal,Daniela Göppner,Jessica C. Hassel,Friedegund Meier,Julia K. Tietze,Ioannis Thomas,Carsten Weishaupt,Martin Leverkus,Renate Ursula Wahl,Ursula Dietrich,Claus Garbe,Michael C. Kirchberger,Thomas Eigentler,Carola Berking,Anja Gesierich,Angela M. Krackhardt,Dirk Schadendorf,Gerold Schuler,Reinhard Dummer,Lucie Heinzerling +27 more
TL;DR: Anti-PD1 antibodies can induce a plethora of irAEs, and the knowledge of them will allow prompt diagnosis and improve the management resulting in decreased morbidity.
Journal ArticleDOI
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
TL;DR: Advances in the understanding of the mechanism of chemotherapy resistance offer the hope for improved results with chemotherapy, and the triumvirate of more effective chemotherapy, immunotherapy, and targeted therapy are likely to be combined with one another for significant advances in melanoma over the coming few years.
Journal ArticleDOI
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.
Lisa Zimmer,Simone M. Goldinger,Lars Hofmann,Carmen Loquai,Selma Ugurel,Ioannis Thomas,Maria I. Schmidgen,Ralf Gutzmer,Jochen Utikal,Daniela Göppner,Jessica C. Hassel,Friedegund Meier,Julia K. Tietze,Andrea Forschner,Carsten Weishaupt,Martin Leverkus,Renate Ursula Wahl,Ursula Dietrich,Claus Garbe,Michael C. Kirchberger,Thomas Eigentler,Carola Berking,Anja Gesierich,Angela M. Krackhardt,Dirk Schadendorf,Gerold Schuler,Reinhard Dummer,Lucie Heinzerling +27 more
TL;DR: Anti-PD-1 antibodies can induce a plethora of irAEs and the knowledge of them will allow prompt diagnosis and improve the management resulting in decreased morbidity.
Journal ArticleDOI
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Alexander Martens,Kilian Wistuba-Hamprecht,Marnix H Geukes Foppen,Jianda Yuan,Michael A. Postow,Phillip Wong,Emanuela Romano,Amir Khammari,Brigitte Dréno,Mariaelena Capone,Paolo A. Ascierto,Anna Maria Di Giacomo,Michele Maio,Bastian Schilling,Antje Sucker,Dirk Schadendorf,Jessica C. Hassel,Thomas Eigentler,Peter Martus,Jedd D. Wolchok,Christian U. Blank,Graham Pawelec,Claus Garbe,Benjamin Weide +23 more
TL;DR: A baseline signature of low LDH, AMC, and MDSCs as well as high AEC, Tregs, and RLC is associated with favorable outcome following ipilimumab.